A review of the use of clozapine levels to guide treatment and determine cause of death

Australian and New Zealand Journal of Psychiatry

Volumn 46, Issue 9, 2012, Pages 816-825

  Stark, Anne ^a   Scott, James ^a,b,c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

Author keywords

Clozapine; levels; mortality; toxicity

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; OMEPRAZOLE; PHENYTOIN; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; AUTOPSY; BLOOD VESSEL; CARDIOMYOPATHY; CAUSE OF DEATH; CORRELATION ANALYSIS; DIABETIC KETOACIDOSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; HUMAN; HYPERICUM PERFORATUM; HYPOTENSION; LIVER FAILURE; MEDLINE; MORTALITY; MYOCARDITIS; NEUTROPENIA; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEPSIS; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; BLOOD; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; AUTOPSY; CAUSE OF DEATH; CLOZAPINE; HUMANS; PSYCHOTIC DISORDERS;

EID: 84873690715     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412438871     Document Type: Review

References (101)

1. Aichhorn W, Whitworth AB, Weiss EM, et al. Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Safety. 2006 ; 29: 587-598
2. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry. 2004 ; 65: 464-470
3. Bell R, McLaren A, Copolov D. How reliable are reported plasma clozapine levels?. Australian and New Zealand Journal of Psychiatry. 2001 ; 35: 468-473
4. Bell R, McLaren A, Galanos J, et al. The clinical use of plasma clozapine levels. Australian and New Zealand Journal of Psychiatry. 1998 ; 32: 567-574
5. Bennett JA, Keck PE. A target-dose finding study of clozapine in patients with schizophrenia. Annals of Clinical Psychiatry. 1996 ; 8: 19-21
6. Buckley PF, Friedman L, Krowinski AC, et al. Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment-refractory schizophrenia. Schizophrenia Research. 2001 ; 49: 225-227
7. Butzbach DM. The influence of putrefaction and sample storage on post-mortem toxicology results. Forensic Science Medicine and Pathology. 2010 ; 6: 35-45
8. Chang WH, Lin SK, Lane HY, et al. Clozapine dosages and plasma drug concentrations. Journal of the Formosan Medical Association. 1997 ; 96: 599-605
9. Chong SA, Tan CH, Khoo YM, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Therapeutic Drug Monitoring. 1997 ; 19: 219-223
10. Cook DS, Braithwaite RA, Hale KA. Estimating antemortem drug concentrations from postmortem blood samples: the influence of postmortem redistribution. Journal of Clinical Pathology. 2000 ; 53: 282-285
11. Cooper TB. Clozapine plasma level monitoring: Current status. Psychiatric Quarterly. 1996 ; 67: 297-311
12. Cormac I, Brown A, Creasey S, et al. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatrica Scandinavica. 2010 ; 121: 393-397
13. Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1993-2007. Therapeutic Drug Monitoring. 2010 ; 32: 438-447
14. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology. 2004 ; 24: 192-208
15. De Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2003 ; 27: 1059-1063
16. De Leon J, Simpson GM. Postmortem clozapine levels. Journal of Clinical Psychopharmacology. 2004 ; 24: 100-101
17. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991 ; 41: 369-371
18. Dhillon R, Bastiampillai T, Tee K, et al. Clozapine and associated QTc prolongation. Australian and New Zealand Journal of Psychiatry. 2011 ; 45: 1098-1099
19. Drummer OH, Gerostamoulos J. Postmortem drug analysis: Analytical and toxicological aspects. Therapeutic Drug Monitoring. 2002 ; 24: 199-209
20. Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002 ; 27: 1050-1055
21. Ferner RE. Post-mortem clinical pharmacology. British Journal of Clinical Pharmacology. 2008 ; 66: 430-443
22. Flanagan RJ, Amin A, Seinen W. Effect of post-mortem changes on peripheral and central whole blood and tissue clozapine and norclozapine concentrations in the domestic pig (Sus scrofa). Forensic Science International. 2003 ; 132: 9-17
23. Flanagan RJ, Spencer EP, Morgan PE, et al. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forensic Science International. 2005 ; 155: 91-99
24. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy?. Clinical Pharmacokinetics. 1997 ; 32: 93-100
25. Freudenreich O, McEvoy JP, Cooper TB. Monitoring of clozapine blood levels in the real world. Journal of Clinical Psychopharmacology. 1996 ; 16: 90-91
26. Frick A, Kopitz J, Bergemann N. Omeprazole reduces clozapine plasma concentrations - a case report. Pharmacopsychiatry. 2003 ; 36: 121-123
27. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Review of Psychiatry. 1995 ; 3: 1-9
28. Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. Journal of Psychopharmacology. 2003 ; 17: 234-238
29. Gross A, Joutsiniemi SL, Rimon R, et al. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry. 2004 ; 37: 119-122
30. Haack MJ, Bak M, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. European Neuropsychopharmacology. 2003 ; 13: 381-385
31. Hagg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Safety. 2009 ; 8: 537-547
32. Hargrove VM, McCutcheon JR. Comparison of drug concentrations taken from clamped and unclamped femoral vessels. Journal of Analytical Toxicology. 2008 ; 32: 621-625
33. Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. American Journal of Psychiatry. 1990 ; 147: 1471-1475
34. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research. 2005 ; 73: 139-145
35. Hilberg T, Bugge A, Beylich KM, et al. An animal model of postmortem amitryptyline redistribution. Journal of Forensic Sciences. 1993 ; 38: 81-90
36. Hilberg T, Rogde S, Morland J. Postmortem drug redistribution - human cases related to results in experimental animals. Journal of Forensic Sciences. 1999 ; 44: 3-9
37. Jaskiw GE, Konicki PE, Fuller MA. Clozapine: toxicity vs. postmortem redistribution. Schizophrenia Research. 2008 ; 101: 344-345
38. Kerswill RM, Vicente MR. Clozapine and postmortem redistribution. American Journal of Psychiatry. 2003 ; 160: 184
39. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999 ; 354: 1841-1845
40. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry. 1995 ; 152: 179-182
41. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Journal of Clinical Psychiatry. 1999 ; 60: 36-40
42. Liu HC, Chang WH, Wei FC, et al. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Therapeutic Drug Monitoring. 1996 ; 18: 200-207
43. Llorca PM, Lancon C, Disdier B, et al. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. Journal of Psychiatry & Neuroscience. 2002 ; 27: 30-37
44. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Annals of Pharmacotherapy. 2010 ; 44: 727-732
45. Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997 ; 112: 1707-1709
46. Malalagama G, Bastiampillai T, Dhillon R. Clozapine prescription patterns in Australia over the last 10 years. Australian and New Zealand Journal of Psychiatry. 2011 ; 45: 498-499
47. Matsuda KT, Cho MC, Lin KM, et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacology Bulletin. 1996 ; 32: 253-257
48. Mauri MC, Volonteri LS, Fiorentini A, et al. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophrenia Research. 2004 ; 66: 197-198
49. McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring clozapine in Christchurch. Australasian Psychiatry. 2008 ; 16: 263-267
50. Meltzer HY. Suicide in schizophrenia: Risk factors and clozapine treatment. Journal of Clinical Psychiatry. 1998 ; 59: 15-20
51. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry. 2003 ; 60: 82-91
52. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology. 2005 ; 25: 32-41
53. Meyer JM. Individual changes in clozapine levels after smoking cessation: Results and a predictive model. Journal of Clinical Psychopharmacology. 2001 ; 21: 569-574
54. Miller DD. Review and management of clozapine side effects. Journal of Clinical Psychiatry. 2000 ; 61: 14-17
55. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. Journal of Clinical Psychiatry. 1994 ; 55: 117-121
56. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. British Journal of Clinical Pharmacology. 2001 ; 52: 45S - 54S
57. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Journal of Clinical Psychiatry. 2005 ; 66: 534-538
58. Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. European Journal of Clinical Pharmacology. 2010 ; 66: 797-803
59. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010 ; 35: 1997-2004
60. Oo TZ, Wilson JF, Naidoo D, et al. Therapeutic monitoring of clozapine in Australia: The need for consensus. Therapeutic Drug Monitoring. 2006 ; 28: 696-699
61. Oyewumi LK, Cernovsky ZZ, Freeman DJ, et al. Relation of blood counts during clozapine treatment to serum concentrations of clozapine and nor-clozapine. Canadian Journal of Psychiatry. 2002 ; 47: 257-261
62. Oyewumi LK, Freeman DJ, Vollick D. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration?. Therapeutic Drug Monitoring. 1995 ; 17: 137-141
63. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. Journal of Clinical Psychopharmacology. 2001 ; 21: 398-407
64. Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. American Journal of Health-System Pharmacy. 2008 ; 65: 1825-1829
65. Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2002 ; 26: 473-480
66. Paz E, Bouzas L, Hermida J, et al. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clinical Biochemistry. 2008 ; 41: 603-606
67. Pelissier-Alicot AL, Gaulier JM, Champsaur P, et al. Mechanisms underlying postmortem redistribution of drugs: a review. Journal of Analytical Toxicology. 2003 ; 27: 533-544
68. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacology Bulletin. 2001 ; 35: 19-29
69. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Journal of Clinical Psychiatry. 1994 ; 55: 94-97
70. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry. 1994 ; 55: 133-136
71. Pounder DJ, Jones GR. Post-mortem drug redistribution - a toxicological nightmare. Forensic Science International. 1990 ; 45: 253-263
72. Raaska K, Raitasuo V, Laitila J, et al. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic & Clinical Pharmacology & Toxicology. 2004 ; 94: 13-18
73. Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clinical Neuropharmacology. 2008 ; 31: 347-352
74. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Current Opinion in Psychiatry. 2007 ; 20: 131-137
75. Rodda KE, Drummer OH. The redistribution of selected psychiatric drugs in post-mortem cases. Forensic Science International. 2006 ; 164: 235-239
76. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology. 2004 ; 24: 70-78
77. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry. 2005 ; 39: 1-30
78. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Smoking and schizophrenia. Psychiatria Danubina. 2009 ; 21: 371-375
79. Sandson NB, Cozza KL, Armstrong SC, et al. Clozapine case series. Psychosomatics. 2007 ; 48: 170-175
80. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical Pharmacokinetics. 2003 ; 42: 607-618
81. Shepherd MF, Lake KD, Kamps MA. Postmortem changes and pharmacokinetics: review of the literature and case report. Annals of Pharmacotherapy. 1992 ; 26: 510-514
82. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. Journal of Clinical Psychiatry. 2009 ; 70: 1041-1050
83. Sparshatt A, Taylor D, Patel MX, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. Journal of Clinical Psychiatry. 2011 ; 72: 1108-1123
84. Spina E, Avenoso A, Facciola G, et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International Clinical Psychopharmacology. 1998 ; 13: 141-145
85. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000a ; 148: 83-89
86. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry. 2000b ; 33: 213-217
87. MIMS Annual 2010. Swannick G, ed. Sydney, Australia: CMPMedica Pty Ltd ; 2010
88. Tang YL, Mao P, Li FM, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. British Journal of Clinical Pharmacology. 2007 ; 64: 49-56
89. Taylor D. Pharmacokinetic interactions involving clozapine. British Journal of Psychiatry. 1997 ; 171: 109-112
90. Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. Journal of Psychopharmacology. 2000 ; 14: 409-418
91. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 ; 374: 620-627
92. Van Troostwijk L, Koopmans RP, Vermeulen HDB, et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. European Journal of Pharmaceutical Sciences. 2003 ; 20: 451-457
93. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. American Journal of Psychiatry. 1996 ; 153: 1579-1584
94. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology. 1997 ; 8: 671-677
95. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. Journal of Neuropsychiatry and Clinical Neurosciences. 1994 ; 6: 250-256
96. Wong JO, Leung SP, Mak T, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Progress in Neuro-psychopharmacol & Biological Psychiatry. 2006 ; 30: 251-264
97. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. Canadian Medical Association Journal. 2002 ; 166: 1185-1186
98. Xiang YQ, Zhang ZJ, Weng YZ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophrenia Research. 2006 ; 83: 201-210
99. Yarema MC, Becker CE. Key concepts in postmortem drug redistribution. Clinical Toxicology. 2005 ; 43: 235-241
100. Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. International Clinical Psychopharmacology. 2007 ; 22: 238-243
101. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. International Clinical Psychopharmacology. 2002 ; 17: 141-143